Novel concepts to target CD22 with CAR T-cell therapy for R/R B-ALL

Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a difficult to treat disease with poor prognosis. Two...

Hyper-CVAD with sequential blinatumomab for the treatment of adult patients with newly diagnosed Philadelphia chromosome-negative B-cell ALL

Despite high rates of complete remissions, long-term...

Genetic markers in the prognosis of patients with ALL

Despite much research, the mutational landscape of patients with acute lymphoblastic leukemia (ALL) remains relatively poorly characterized,...

Blinatumomab prior to CD19 CAR T-cell therapy for the treatment of relapse/refractory ALL

Regulatory agencies in Europe and the United States have approved two agents that target CD19 for the...

Supplemental biologics license application submitted for brexucabtagene autoleucel for use in R/R B-cell ALL

Relapsed or refractory (R/R) acute lymphoblastic lymphoma (ALL) is associated with poor...

Advances of cell therapies in China: Reducing manufacturing time with FasT dual CAR T-cells

The Multiple Myeloma Hub previously summarised activities on chimeric antigen receptor (CAR) T cells in...

What is new in CAR T-cell therapy for ALL?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the ALL Hub spoke to Arnon Nagler, Tel Aviv...

NCCN COVID-19 vaccination recommendations for patients with hematologic malignancies

Patients with cancer are at high risk of COVID-19-associated complications and, accordingly, the preliminary...

Advances of cell therapies in China: Reducing manufacturing time with FasT dual CAR T-cells

The Multiple Myeloma Hub previously summarised activities on chimeric antigen receptor (CAR) T cells in...

Development of childhood B-ALL, triggering factors, and prospective treatments

Childhood B-cell acute lymphoblastic leukemia (B-ALL), also termed B-cell precursor ALL, is a malignant disease...

NCCN COVID-19 vaccination recommendations for patients with hematologic malignancies

Patients with cancer are at high risk of COVID-19-associated complications and, accordingly, the preliminary...

Novel concepts to target CD22 with CAR T-cell therapy for R/R B-ALL

Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a difficult to treat disease with poor prognosis. Two...